Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
05 août 2019 08h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for...
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
28 mai 2019 09h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 28, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering...
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
10 mai 2019 08h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
10 mai 2019 08h00 HE
|
Galectin Therapeutics Inc.
Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. Rights expire at 5:00 PM Eastern on May 23, 2019 ...
Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
15 avr. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key...
Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
02 avr. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...
Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
22 mars 2019 10h19 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins,...
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
06 mars 2019 08h03 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
06 mars 2019 08h02 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement...
Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
06 mars 2019 08h00 HE
|
Galectin Therapeutics Inc.
Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga.,...